Protara therapeutics, inc. TARA.US Overview
TARA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
TARA Current Performance
3.28%
Protara therapeutics, inc.
1.60%
Avg of Sector
0.32%
S&P500
TARA Key Information
TARA Revenue by Segments
Browsing restrictions can be lifted for a fee.
TARA Net Income
Browsing restrictions can be lifted for a fee.
TARA Cash Flow
Browsing restrictions can be lifted for a fee.
TARA Profit Margin
Browsing restrictions can be lifted for a fee.
TARA PE Ratio River
Browsing restrictions can be lifted for a fee.
TARA Financial Forecast
Browsing restrictions can be lifted for a fee.
TARA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
TARA Profile
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Price of TARA
TARA FAQ
When is TARA's latest earnings report released?
The most recent financial report for Protara therapeutics, inc. (TARA) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TARA's short-term business performance and financial health. For the latest updates on TARA's earnings releases, visit this page regularly.
How much debt does TARA have?
As of the end of the reporting period, Protara therapeutics, inc. (TARA) had total debt of 4.23M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does TARA have?
At the end of the period, Protara therapeutics, inc. (TARA) held Total Cash and Cash Equivalents of 91.46M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is TARA's EPS continuing to grow?
According to the past four quarterly reports, Protara therapeutics, inc. (TARA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.29. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TARA?
Protara therapeutics, inc. (TARA)'s Free Cash Flow (FCF) for the period is -14.76M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 42.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of TARA?
The latest valuation data shows Protara therapeutics, inc. (TARA) has a Price-To-Earnings (PE) ratio of -2.86 and a Price/Earnings-To-Growth (PEG) ratio of 0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.